Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial.
Gray JC, Weston R, Owens C, Canete A, Gambart M, De Wilde B, Nysom K, van Eijkelenburg N, Ladenstein R, Castellano A, Gerber NU, Marshall LV, Barone G, Rubio-San-Simon A, Ng A, Vaidya S, Gallego S, Makin G, Burke GAA, McCarthy A, Murphy D, Zwaan CM, López-Almaraz R, Jannier S, Thebaud E, Corradini N, Yeomanson D, Howell L, Tweddle DA, Elliott M, Hobin D, Valteau-Couanet D, Schleiermacher G, Chastagner P, Defachelles AS, Brichard B, George S, Chesler L, Laidler J, Firth C, Holt G, Moroz V, Pearson ADJ, Gates S, Wheatley K, Kearns P, Moreno L.
Gray JC, et al. Among authors: canete a.
J Clin Oncol. 2026 Jan 20;44(3):176-187. doi: 10.1200/JCO-25-01868. Epub 2025 Dec 12.
J Clin Oncol. 2026.
PMID: 41385757
Free PMC article.
Clinical Trial.